SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
IRadimed Corporation (IRMD) trades at a trailing P/E of 55.0, forward P/E of 46.3. Trailing earnings yield is 1.82%, forward earnings yield 2.16%. PEG 3.29. Graham Number is $17.17.
Criteria proven by this page:
- VALUE (27/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 55.0); PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 3.29).
- Forward P/E 46.3 (down from trailing 55.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 3.29 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 1.82% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.16% as earnings recover.
- Analyst consensus target $120.00 (+28.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 79/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
27/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IRMD
Valuation Multiples
P/E (TTM)55.0
Forward P/E46.3
PEG Ratio3.29
Forward PEG3.01
P/B Ratio13.07
P/S Ratio14.80
EV/EBITDA41.1
Per Share Data
EPS (TTM)$1.76
Forward EPS (Est.)$2.02
Book Value / Share$7.43
Revenue / Share$6.58
FCF / Share$1.32
Yields & Fair Value
Earnings Yield1.82%
Forward Earnings Yield2.16%
Dividend Yield1.25%
Graham Number$17.17
SharesGrow IV$64.16 (-31.4%)
Analyst Target$120.00 (+28.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
16.6 |
-11.32 |
3.77 |
3.70 |
- |
| 2017 |
322.5 |
-3.49 |
4.89 |
6.98 |
- |
| 2018 |
47.0 |
0.05 |
7.06 |
9.73 |
- |
| 2019 |
27.4 |
0.43 |
4.75 |
6.85 |
- |
| 2020 |
201.9 |
-2.32 |
4.50 |
8.72 |
- |
| 2021 |
61.2 |
0.10 |
7.90 |
13.64 |
- |
| 2022 |
27.7 |
0.81 |
4.82 |
6.67 |
3.53% |
| 2023 |
34.8 |
1.04 |
8.38 |
9.13 |
2.21% |
| 2024 |
36.2 |
3.08 |
8.03 |
9.51 |
1.96% |
| 2025 |
55.1 |
3.35 |
13.08 |
14.77 |
1.22% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.60 |
$32.5M |
$7.21M |
22.2% |
| 2017 |
$0.04 |
$23.08M |
$499.76K |
2.2% |
| 2018 |
$0.52 |
$30.44M |
$6.3M |
20.7% |
| 2019 |
$0.78 |
$38.52M |
$9.63M |
25% |
| 2020 |
$0.11 |
$31.72M |
$1.37M |
4.3% |
| 2021 |
$0.74 |
$41.81M |
$9.33M |
22.3% |
| 2022 |
$1.02 |
$53.3M |
$12.83M |
24.1% |
| 2023 |
$1.35 |
$65.56M |
$17.19M |
26.2% |
| 2024 |
$1.50 |
$73.24M |
$19.23M |
26.3% |
| 2025 |
$1.75 |
$83.81M |
$22.48M |
26.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.08 |
$2.05 – $2.11 |
$91.92M |
$90.96M – $92.87M |
2 |
| 2027 |
$2.32 |
$2.29 – $2.35 |
$101.14M |
$100.08M – $102.18M |
2 |
| 2028 |
$2.67 |
$2.63 – $2.71 |
$121.1M |
$119.84M – $122.35M |
1 |
| 2029 |
$3.04 |
$3.00 – $3.08 |
$131.9M |
$130.52M – $133.26M |
1 |
| 2030 |
$3.43 |
$3.38 – $3.48 |
$145.9M |
$144.38M – $147.41M |
1 |
